Propanc Biopharma's PRP Shows >90% Tumor Growth Inhibition in Pancreatic Cancer Models
Event summary
- Propanc Biopharma's PRP achieved >90% tumor growth inhibition in preclinical pancreatic cancer models.
- PRP extended median overall survival by >2.5-fold in treated animals.
- PRP demonstrated enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care treatments.
- Propanc plans to accelerate Phase 1b First-in-Human study in advanced solid tumors.
- PRP holds FDA Orphan Drug Designation for pancreatic cancer.
The big picture
Propanc Biopharma's PRP offers a differentiated approach to pancreatic cancer treatment by targeting cancer stem cells and remodeling the tumor microenvironment. This contrasts with existing therapies like Revolution Medicines' daraxonrasib, which focuses on RAS pathway inhibition. The company's progress could expand treatment options for a disease with limited durable therapies and high unmet medical need.
What we're watching
- Clinical Translation
- How Propanc's preclinical results will translate into clinical outcomes in the upcoming Phase 1b study.
- Combination Therapies
- Whether PRP can be effectively combined with existing treatments like RAS inhibitors or chemotherapy.
- Regulatory Pathway
- The pace at which Propanc can secure regulatory approvals for PRP given its Orphan Drug Designation.
Related topics